Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products.

ABSTRACT:

Background aims

Chimeric antigen receptor (CAR) T cells have demonstrated remarkable efficacy against hematological malignancies; however, they have not experienced the same success against solid tumors such as glioblastoma (GBM). There is a growing need for high-throughput functional screening platforms to measure CAR T-cell potency against solid tumor cells.

Methods

We used real-time, label-free cellular impedance sensing to evaluate the potency of anti-disialoganglioside (GD2) targeting CAR T-cell products against GD2+ patient-derived GBM stem cells over a period of 2 days and 7 days in vitro. We compared CAR T products using two different modes of gene transfer: retroviral transduction and virus-free CRISPR-editing. Endpoint flow cytometry, cytokine analysis and metabolo

SUBMITTER: Logun M 

PROVIDER: S-EPMC10159906 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature